Russell Investments Group Ltd. Has $775,000 Position in BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• Russell Investments Group Ltd. increased its position in BioCryst Pharmaceuticals by 269.5%, owning 103,329 shares valued at approximately $775,000 by the end of the first quarter.
• The company reported earnings of $0.15 EPS for the last quarter, surpassing the expected $0.03 EPS, with revenues of $163.35 million, up 49.5% year-over-year.
• Analysts have a positive outlook on BioCryst Pharmaceuticals, with a consensus price target of $16.70 and nine analysts rating it as a "Buy."

Russell Investments Group Ltd. boosted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 269.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 103,329 shares of the biotechnology company's stock after purchasing an additional 75,363 shares during the period. Russell Investments Group Ltd.'s holdings in BioCryst Pharmaceuticals were worth $775,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in BCRX. Raymond James Financial Inc. bought a new position in BioCryst Pharmaceuticals in the fourth quarter valued at $80,000. Mariner LLC grew its position in shares of BioCryst Pharmaceuticals by 32.1% in the 4th quarter. Mariner LLC now owns 13,258 shares of the biotechnology company's stock valued at $100,000 after acquiring an additional 3,224 shares during the period. MetLife Investment Management LLC grew its position in shares of BioCryst Pharmaceuticals by 6.0% in the 4th quarter. MetLife Investment Management LLC now owns 126,949 shares of the biotechnology company's stock valued at $955,000 after acquiring an additional 7,199 shares during the period. Tower Research Capital LLC TRC grew its position in shares of BioCryst Pharmaceuticals by 84.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 23,083 shares of the biotechnology company's stock valued at $174,000 after acquiring an additional 10,583 shares during the period. Finally, Hsbc Holdings PLC grew its position in shares of BioCryst Pharmaceuticals by 33.9% in the 4th quarter. Hsbc Holdings PLC now owns 90,061 shares of the biotechnology company's stock valued at $677,000 after acquiring an additional 22,814 shares during the period. Institutional investors own 85.88% of the company's stock.

Insiders Place Their Bets

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the sale, the director owned 65,352 shares in the company, valued at $556,145.52. The trade was a 51.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 5.10% of the stock is owned by company insiders.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock traded down $0.02 during midday trading on Thursday, hitting $8.27. The company's stock had a trading volume of 1,576,243 shares, compared to its average volume of 2,181,882. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.01 and a 1-year high of $11.31. The company has a 50-day moving average price of $8.54 and a two-hundred day moving average price of $8.77. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -45.94, a PEG ratio of 1.88 and a beta of 1.13.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.12. The business had revenue of $163.35 million during the quarter, compared to analyst estimates of $149.59 million. During the same quarter last year, the firm earned ($0.06) EPS. BioCryst Pharmaceuticals's revenue for the quarter was up 49.5% compared to the same quarter last year. Sell-side analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Wall Street Analyst Weigh In

BCRX has been the subject of a number of analyst reports. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 26th. Wedbush lifted their price objective on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a research report on Monday, June 30th. Royal Bank Of Canada reissued an "outperform" rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Barclays lifted their price objective on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a research report on Wednesday, May 7th. Finally, Bank of America raised their target price on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Tuesday, July 1st. Nine equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $16.70.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.